Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers - Full Text View

Purpose

It is proposed that patients with skin disease due to presumed immunologic, genetic or viral-induced abnormalities, patients with neurological degenerations, and normal controls be evaluated with various in vitro studies of immunologic, genetic, and virologic function. This is to include studies of peripheral blood (cells and serum) as well as studies of skin obtained with a biopsy instrument. In addition, studies of gastrointestinal function will be performed where appropriate.

Condition

Healthy
Muscular Dystrophy
Retinal Degeneration
Skin Diseases
Virus Diseases

Genetics Home Reference related topics:

X-linked juvenile retinoschisis

MedlinePlus related topics:

Muscular Dystrophy Skin Conditions

U.S. FDA Resources

Study Type:	Observational

Official Title:	Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

Further study details as provided by National Institutes of Health Clinical Center (CC):

Study Start Date:	July 1978
Estimated Study Completion Date:	June 2000

Detailed Description:

It is proposed that patients with skin disease due to presumed immunologic, genetic or viral-induced abnormalities, patients with neurological degenerations, and normal controls be evaluated with various in vitro studies of immunologic, genetic, and virologic function. This is to include studies of peripheral blood (cells and serum) as well as studies of skin obtained with a biopsy instrument. In addition, studies of gastrointestinal function will be performed where appropriate.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Patients with skin diseases of presumed genetic, immunologic, or virologic origin are eligible.

Patients with neurological degenerations are eligible, including patients with inflammatory, neoplastic and viral skin diseases and also heterozygous carriers of such inherited diseases.

Volunteers without skin diseases are eligible, except children.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001164

Locations


United States, Maryland
	National Cancer Institute (NCI)
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Cancer Institute (NCI)

More Information

Publications:

Kraemer KH, Coon HG, Petinga RA, Barrett SF, Rahe AE, Robbins JH. Genetic heterogeneity in xeroderma pigmentosum: complementation groups and their relationship to DNA repair rates. Proc Natl Acad Sci U S A. 1975 Jan;72(1):59-63.

Yaoita H, Katz SI. Immunoelectronmicroscopic localization of IgA in skin of patients with dermatitis herpetiformis. J Invest Dermatol. 1976 Oct;67(4):502-6.

Study ID Numbers:	780099, 78-C-0099
First Received:	November 3, 1999
Last Updated:	March 4, 2008
ClinicalTrials.gov Identifier:	NCT00001164
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Genetic Evaluation

Immunologic Evaluations

Inflammatory Skin Disease

Muscular Dystrophies

Neoplastic Skin Diseases

Neuronal Degenerations

Retinal Degenerations

Viral Diseases

Study placed in the following topic categories:

Skin Diseases

Eye Diseases

Retinal Degeneration

Healthy

Virus Diseases

Muscular Dystrophies

Muscular Diseases

Muscular Disorders, Atrophic

Musculoskeletal Diseases

Neuromuscular Diseases

Genetic Diseases, Inborn

Atrophy

Muscular dystrophy

Retinal Diseases

Retinal degeneration

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	National Cancer Institute (NCI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001164